Ferrero 2010.

Methods	Randomised controlled trial, single centre
Participants	144 women Inclusion criteria: no specific details but included women who had had moderate or severe OHSS or who had been at risk of OHSS during their first IVF/ICSI cycle with a mid‐luteal long agonist protocol Exclusion criteria: no details Setting and timing: Italy; no details of timing Baseline characteristics: not stated
Interventions	Antagonist ‐ cetrorelix 0.25 mg/day starting on day 3 of the menstrual cycle Agonist ‐ triptorelin 0.1 mg/day starting on day 21 of the menstrual cycle Ovarian stimulation was achieved with rFSH initiated on day 3 of the cycle at a maximum dose of 150 IU and dose adjusted depending on ovarian response Luteal phase support ‐ with micronised progesterone vaginal gel (no other details) Follow‐up ‐ followed‐up to live birth
Outcomes	Live birth, clinical pregnancy, cancellation rate, oocytes retrieved
Notes	As no denominators for groups are given, the data cannot be included in a meta‐analysis
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	No details
Allocation concealment (selection bias)	Unclear risk	No details
Blinding (performance bias and detection bias) All outcomes	Unclear risk	Open label but blinding unlikely to effect fertility outcome. No details of blinding of outcome assessors
Incomplete outcome data (attrition bias) All outcomes	Unclear risk	Although the abstract states that there were 144 women randomised, there are no other denominators to indicate how many women were allocated to each group. No details on withdrawals or losses to follow‐up
Selective reporting (reporting bias)	Unclear risk	Conference abstract only. Outcomes are not pre‐specified. OHSS not reported
Other bias	Unclear risk	Conference abstract only. Groups were reported as being similar at baseline